Hemab Therapeutics Holdings, Inc. Common Stock Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) holds an ST Score of 72.4 out of 100 (B+), with its strongest factor being Financial Strength (A+) and its weakest Forecast (B-). Analysts rate COAG Buy across 3 ratings with a $51.40 average price target (+0.4% vs the current $37.97).
- Strongest
- Financial StrengthA+
- Weakest
- ForecastB-
All factor grades
- Financial StrengthA+
- ValuationA-
- ProfitabilityA-
- GrowthB
- MomentumB-
- ForecastB-
Contact
COAG stock: frequently asked questions
What is COAG's ST Score?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) has an ST Score of 72.4 out of 100, an overall grade of B+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is COAG a buy, sell, or hold?
Wall Street's consensus rating on COAG is Buy based on 3 analyst ratings. Our own ST Score grades it B+ (72.4/100). This is data, not investment advice — always do your own research.
What is COAG's valuation grade?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is COAG's growth grade?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is COAG's profitability grade?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) earns a profitability grade of A-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is COAG's financial strength grade?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for COAG?
The average analyst price target for Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is $51.40 from 3 analysts, which is +0.4% versus the recent price of $37.97.